WO2023159086 - QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS
National phase entry:
Publication Number
WO/2023/159086
Publication Date
24.08.2023
International Application No.
PCT/US2023/062687
International Filing Date
15.02.2023
Title **
[English]
QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS
[French]
COMPOSÉS DE QUINAZOLINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PROTÉINES KRAS MUTANTES
Applicants **
AMGEN INC.
Inventors
LI, Xiaofen
ZHAO, Wei
WURZ, Ryan
YAMANO, Michael
HOT, Imelda
RAHIMOFF, Rene
PETTUS, Liping
MEDINA, Jose
LANMAN, Brian
Priority Data
63/310,915
16.02.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3530 | |
| EPO | Filing, Examination, Granting | 24309 | |
| Japan | Filing, Examination, Granting | 2954 | |
| South Korea | Filing, Examination, Granting | 3705 | |
| USA | Filing, Examination, Granting | 13590 |
Total:
48,088
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S or G12C. The compounds have a general Formula I : (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.[French]
La présente invention concerne des composés utiles pour l'inhibition de KRAS G12D, G12V, G12A, G12S ou G12C. Les composés ont une formule générale I : (I) dans laquelle les variables de formule I sont définies dans la description. La présente invention concerne également des compositions pharmaceutiques comprenant les composés, des utilisations des composés, et des compositions pour le traitement, par exemple, du cancer.